Remarkable Survival Achieved Through Innovative Treatment
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) has made headlines recently with an extraordinary update regarding their drug Namodenoson. This innovative treatment has led to an incredible nine-year overall survival for a patient suffering from advanced liver cancer, demonstrating a complete response to the drug.
The patient was part of a Phase II study, which has now concluded but continues to receive Namodenoson under a compassionate use program. Even after nine years, the patient is cancer-free, showing significant improvement in their health status, including normalized liver function and an overall quality of life that has drastically improved.
Expanding Horizons: Phase III Trials Underway
As Can-Fite moves forward, they are currently enrolling subjects for a pivotal Phase III study of Namodenoson, targeting patients with advanced hepatocellular carcinoma (HCC). This pivotal research effort is not only ongoing in Israel but also spans across Europe and the U.S. Importantly, the FDA and the European Medicines Agency (EMA) have both approved the study protocol, adding to the credibility and anticipation surrounding this critical trial.
Namodenoson has been awarded Orphan Drug status and Fast Track designation by the FDA, emphasizing its potential in treating this aggressive form of liver cancer. Furthermore, a compassionate use program is currently operational in both Israel and Romania, paving the way for expanded access to this promising treatment.
Strong Voices in the Medical Community
According to Professor Pnina Fishman, the Chief Scientific Officer and Chairperson at Can-Fite, the notable efficacy of Namodenoson combined with its tolerability offers new hope for patients battling HCC. She expressed the aspiration that many patients might experience survival rates reminiscent of the exceptional nine-year response observed in a prior study.
With HCC leading to over 700,000 deaths globally each year, the demand for safe and effective treatments is critical. The market for liver cancer therapies is expected to expand significantly, potentially reaching $6.1 billion by 2027 in G8 nations, according to industry forecasts.
Understanding Namodenoson and Its Mechanism
Namodenoson is a small molecule that demonstrates high affinity for the A3 adenosine receptor (A3AR), making it unique among liver cancer treatments. This receptor is predominantly found in diseased cells, while healthy cells show minimal expression. Such specificity may explain the favorable safety profile of Namodenoson, making it an attractive option for patients with liver cancer.
Moreover, Can-Fite is not just focusing on liver cancer; Namodenoson is also under evaluation in additional clinical trials for conditions such as Metabolic Dysfunction-associated Steatohepatitis (MASH) and pancreatic cancer, showcasing the compound's versatility.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma stands at the forefront of developing novel treatment options for cancer and inflammatory diseases. Their lead drug candidate, Piclidenoson, recently reported impressive topline results from a Phase III trial for psoriasis and has entered another pivotal trial. The company's commitment to innovation is evident in their robust clinical pipeline, which also includes promising candidates aimed at treating various cancers and erectile dysfunction.
With a patient-centric approach and a focus on safety, Can-Fite has engaged over 1,600 participants in clinical studies, continuously striving for breakthroughs that could redefine existing treatment paradigms.
Frequently Asked Questions
What is Namodenoson?
Namodenoson is a small, orally bioavailable drug targeting the A3 adenosine receptor, showing promise in treating liver cancer and more.
How long has the patient survived with Namodenoson?
The patient treated with Namodenoson has achieved an astonishing nine years of survival, remaining cancer-free.
What is Can-Fite BioPharma's main focus?
Can-Fite BioPharma focuses on developing treatments for cancer and inflammatory diseases, emphasizing innovative therapies like Namodenoson.
What does the Phase III clinical study involve?
The Phase III study aims to evaluate the effectiveness of Namodenoson for advanced hepatocellular carcinoma as a second or third-line treatment.
Why is the FDA's approval significant for Namodenoson?
The FDA's approval for orphan drug status and fast track designation highlights the potential of Namodenoson in treating serious conditions like liver cancer.
